Stem cell therapy with CeO2 nanoparticles: an innovative nanopharmaceutical approach for the treatment of retinal degenerative diseases

Name: Stem cell therapy with CeO2 nanoparticles: an innovative nanopharmaceutical approach for the treatment of retinal degenerative diseases Acronym: CELLUX Provider: TAČR Program: EuroNanoMed Coordinator: Technická univerzita v Liberci Duration: 1.1.2020 – 31.12.2022 Grant: 3 930 000 Kč

Project annotation:
The main goal of the CELLUX project is to develop novel CeO2 nanoparticle-based eye drops for the treatment of age-related macular degeneration (AMD) that, when combined with stem cell therapy, not only stops vision degeneration but helps restore it. The TUL team is involved in two work packages studying the behaviour of nanoparticles in simulated biological environments and the safety of nanoparticles in vitro. We are also investigating cellular interactions with nanoparticles and evaluating their antimicrobial properties.

Partners:
Vall d'Hebron Research Institute (VHIR), Spain (vedoucí projektu prof. V. Puntes)
Norwegian Institute for Air Research (NILU), Norway
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
Centre international de recherche en infectiologie (CIRI)/ INSERM, France
Applied Nanoparticles S. L., Spain

Hlavní řešitel za TUL

RNDr. Alena Ševců, Ph.D.

T +420 48535 3805

E alena.sevcu@tul.cz

environmental microbiology, nanotoxicology